The European Association for the Study of Diabetes and the American Diabetes Association urged greater caution in prescribing thiazolidediones, such as GlaxoSmithKline's Avandia and Takeda Pharmaceutical Co. Ltd.'s Actos, in light of recent reports linking Avandia to increased heart attack risk. Both drugs already carry strong warnings about heart failure risks.

Full Story:

Related Summaries